Disease-modifying therapies in Alzheimer's disease**EDITOR'S NOTE: The Journal intended to include this article in the January 2008 supplement, "Leon Thal Symposium on Prevention of Dementia."

Stephen Salloway, Jacobo Mintzer, Myron F. Weiner, Jeffrey L. Cummings

Research output: Contribution to journalArticle

125 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is a chronic, progressive, neurodegenerative disorder that places a substantial burden on patients, their families, and society. The disease affects approximately 5 million individuals in the United States, with an annual cost of care greater than $100 billion. During the past dozen years, several agents have been approved that enhance cognition and global function of AD patients, and recent advances in understanding AD pathogenesis has led to the development of numerous compounds that might modify the disease process. A wide array of antiamyloid and neuroprotective therapeutic approaches are under investigation on the basis of the hypothesis that amyloid beta (Aβ) protein plays a pivotal role in disease onset and progression and that secondary consequences of Aβ generation and deposition, including tau hyperphosphorylation and neurofibrillary tangle formation, oxidation, inflammation, and excitotoxicity, contribute to the disease process. Interventions in these processes with agents that reduce amyloid production, limit aggregation, or increase removal might block the cascade of events comprising AD pathogenesis. Reducing tau hyperphosphorylation, limiting oxidation and excitotoxicity, and controlling inflammation might be beneficial disease-modifying strategies. Potentially neuroprotective and restorative treatments such as neurotrophins, neurotrophic factor enhancers, and stem cell-related approaches are also under investigation.

Original languageEnglish (US)
Pages (from-to)65-79
Number of pages15
JournalAlzheimer's and Dementia
Volume4
Issue number2
DOIs
StatePublished - Mar 2008

Fingerprint

Dementia
Alzheimer Disease
Nerve Growth Factors
Inflammation
Serum Amyloid A Protein
Neurofibrillary Tangles
Amyloid beta-Peptides
Therapeutics
Amyloid
Neurodegenerative Diseases
Cognition
Disease Progression
Stem Cells
Costs and Cost Analysis

Keywords

  • Alzheimer's disease
  • Clinical trials
  • Disease modification
  • Neuroprotection

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

Disease-modifying therapies in Alzheimer's disease**EDITOR'S NOTE : The Journal intended to include this article in the January 2008 supplement, "Leon Thal Symposium on Prevention of Dementia.". / Salloway, Stephen; Mintzer, Jacobo; Weiner, Myron F.; Cummings, Jeffrey L.

In: Alzheimer's and Dementia, Vol. 4, No. 2, 03.2008, p. 65-79.

Research output: Contribution to journalArticle

@article{416f5286b2254f51ba2e7cfcd6a7082d,
title = "Disease-modifying therapies in Alzheimer's disease**EDITOR'S NOTE: The Journal intended to include this article in the January 2008 supplement, {"}Leon Thal Symposium on Prevention of Dementia.{"}",
abstract = "Alzheimer's disease (AD) is a chronic, progressive, neurodegenerative disorder that places a substantial burden on patients, their families, and society. The disease affects approximately 5 million individuals in the United States, with an annual cost of care greater than $100 billion. During the past dozen years, several agents have been approved that enhance cognition and global function of AD patients, and recent advances in understanding AD pathogenesis has led to the development of numerous compounds that might modify the disease process. A wide array of antiamyloid and neuroprotective therapeutic approaches are under investigation on the basis of the hypothesis that amyloid beta (Aβ) protein plays a pivotal role in disease onset and progression and that secondary consequences of Aβ generation and deposition, including tau hyperphosphorylation and neurofibrillary tangle formation, oxidation, inflammation, and excitotoxicity, contribute to the disease process. Interventions in these processes with agents that reduce amyloid production, limit aggregation, or increase removal might block the cascade of events comprising AD pathogenesis. Reducing tau hyperphosphorylation, limiting oxidation and excitotoxicity, and controlling inflammation might be beneficial disease-modifying strategies. Potentially neuroprotective and restorative treatments such as neurotrophins, neurotrophic factor enhancers, and stem cell-related approaches are also under investigation.",
keywords = "Alzheimer's disease, Clinical trials, Disease modification, Neuroprotection",
author = "Stephen Salloway and Jacobo Mintzer and Weiner, {Myron F.} and Cummings, {Jeffrey L.}",
year = "2008",
month = "3",
doi = "10.1016/j.jalz.2007.10.001",
language = "English (US)",
volume = "4",
pages = "65--79",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Disease-modifying therapies in Alzheimer's disease**EDITOR'S NOTE

T2 - The Journal intended to include this article in the January 2008 supplement, "Leon Thal Symposium on Prevention of Dementia."

AU - Salloway, Stephen

AU - Mintzer, Jacobo

AU - Weiner, Myron F.

AU - Cummings, Jeffrey L.

PY - 2008/3

Y1 - 2008/3

N2 - Alzheimer's disease (AD) is a chronic, progressive, neurodegenerative disorder that places a substantial burden on patients, their families, and society. The disease affects approximately 5 million individuals in the United States, with an annual cost of care greater than $100 billion. During the past dozen years, several agents have been approved that enhance cognition and global function of AD patients, and recent advances in understanding AD pathogenesis has led to the development of numerous compounds that might modify the disease process. A wide array of antiamyloid and neuroprotective therapeutic approaches are under investigation on the basis of the hypothesis that amyloid beta (Aβ) protein plays a pivotal role in disease onset and progression and that secondary consequences of Aβ generation and deposition, including tau hyperphosphorylation and neurofibrillary tangle formation, oxidation, inflammation, and excitotoxicity, contribute to the disease process. Interventions in these processes with agents that reduce amyloid production, limit aggregation, or increase removal might block the cascade of events comprising AD pathogenesis. Reducing tau hyperphosphorylation, limiting oxidation and excitotoxicity, and controlling inflammation might be beneficial disease-modifying strategies. Potentially neuroprotective and restorative treatments such as neurotrophins, neurotrophic factor enhancers, and stem cell-related approaches are also under investigation.

AB - Alzheimer's disease (AD) is a chronic, progressive, neurodegenerative disorder that places a substantial burden on patients, their families, and society. The disease affects approximately 5 million individuals in the United States, with an annual cost of care greater than $100 billion. During the past dozen years, several agents have been approved that enhance cognition and global function of AD patients, and recent advances in understanding AD pathogenesis has led to the development of numerous compounds that might modify the disease process. A wide array of antiamyloid and neuroprotective therapeutic approaches are under investigation on the basis of the hypothesis that amyloid beta (Aβ) protein plays a pivotal role in disease onset and progression and that secondary consequences of Aβ generation and deposition, including tau hyperphosphorylation and neurofibrillary tangle formation, oxidation, inflammation, and excitotoxicity, contribute to the disease process. Interventions in these processes with agents that reduce amyloid production, limit aggregation, or increase removal might block the cascade of events comprising AD pathogenesis. Reducing tau hyperphosphorylation, limiting oxidation and excitotoxicity, and controlling inflammation might be beneficial disease-modifying strategies. Potentially neuroprotective and restorative treatments such as neurotrophins, neurotrophic factor enhancers, and stem cell-related approaches are also under investigation.

KW - Alzheimer's disease

KW - Clinical trials

KW - Disease modification

KW - Neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=40749160944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40749160944&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2007.10.001

DO - 10.1016/j.jalz.2007.10.001

M3 - Article

C2 - 18631951

AN - SCOPUS:40749160944

VL - 4

SP - 65

EP - 79

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 2

ER -